---
provider: claude_code
model: claude-opus-5-5
cached: false
start_time: '2026-10-13T20:15:49.915982'
end_time: '2026-10-13T20:17:59.405241'
duration_seconds: 129.49
template_file: templates/disease_pathophysiology_research.md
template_sha: "1e7ea4ee817acfe1dda5f77fafe6f2e8b5927666"
template_variables:
  disease_name: Microcephaly, Facial Dysmorphism, Renal Agenesis, and Ambiguous Genitalia
    Syndrome
  mondo_id: MONDO:0020647
  category: Mendelian
provider_config:
  timeout: 1800
  max_retries: 3
  parameters:
    allowed_domains: []
    claude_executable: claude
    skip_permissions: false
    allowed_tools:
    - WebSearch
    - WebFetch
    add_dirs: []
    timeout: 1800
    min_report_chars: 200
    extra_args: []
run_metadata:
  models_used:
  - claude-opus-5-5
  num_turns: 15
  total_cost_usd: 2.2591828000000005
  session_id: 35d6fff9-9d1e-412e-a2e0-e33f4bcf0938
  stop_reason: end_turn
  permission_denials: 3
  denied_tools:
  - Bash
  - mcp__pubmed__search_articles
  assistant_text_blocks: 2
reference_validation:
  total_references: 11
  verified: 11
  not_found: 0
  unverifiable: 0
  confabulation_rate: 0.0
  quotes_checked: 16
  quotes_valid: 16
  relevance_assessed: 11
  on_topic: 8
  off_topic: 1
  off_topic_references:
  - PMID:25081361
  needs_review: true
  validator_version: 0.3.0
term_validation:
  total_terms: 45
  verified: 45
  not_found: 0
  obsolete: 0
  unverifiable: 0
  confabulation_rate: 0.0
  labels_checked: 19
  labels_matching: 10
  labels_mismatched: 2
  mislabelled_terms:
  - term_id: MONDO:0020647
    reported_labels:
    - MONDO
    ontology_label: microcephaly, facial dysmorphism, renal agenesis, and ambiguous
      genitalia syndrome
  - term_id: HP:0001511
    reported_labels:
    - IUGR / preterm birth
    ontology_label: Intrauterine growth retardation
  labels_variant: 7
  needs_review: true
  adapter: 'ols:'
  validator_version: 0.4.5
---

## Question

# Disease Characteristics Research Template

## Target Disease
- **Disease Name:** Microcephaly, Facial Dysmorphism, Renal Agenesis, and Ambiguous Genitalia Syndrome
- **MONDO ID:** MONDO:0020647 (if available)
- **Category:** Mendelian

## Research Objectives

Please provide a comprehensive research report on **Microcephaly, Facial Dysmorphism, Renal Agenesis, and Ambiguous Genitalia Syndrome** covering all of the
disease characteristics listed below. This report will be used to populate a disease knowledge
base entry. Be thorough and cite primary literature (PMID preferred) for all claims.

For each section, **suggested databases/resources** are listed. These are the first places
you should search for information on each topic.

---

### 1. Disease Information
> **Search first:** OMIM, Orphanet, ICD-10/ICD-11, MeSH, PubMed

- What is the disease? Provide a concise overview.
- What are the key identifiers? (OMIM, Orphanet, ICD-10/ICD-11, MeSH, Mondo)
- What are the common synonyms and alternative names?
- Is the information derived from individual patients (e.g., EHR) or aggregated disease-level resources?

### 2. Etiology

- **Disease Causal Factors**: What are the primary causes? (genetic, environmental, infectious, mechanistic)
- **Risk Factors**:
  > **Search first:** PubMed, Cochrane Library, UpToDate, clinical guidelines, ClinVar, ClinGen, GWAS Catalog, PheGenI, CTD, CDC, WHO, epidemiological databases
  - Genetic risk factors (causal variants, susceptibility loci, modifier genes)
  - Environmental risk factors (toxins, lifestyle, occupational exposures, age, sex, family history)
- **Protective Factors**:
  > **Search first:** PubMed, Cochrane Library, clinical trial databases, GWAS Catalog, gnomAD, WHO, CDC, nutrition databases
  - Genetic protective factors (protective variants, modifier alleles)
  - Environmental protective factors (diet, lifestyle, exposures that reduce risk)
- **Gene-Environment Interactions**: How do genetic and environmental factors interact to influence disease?
  > **Search first:** CTD, PubMed, PheGenI, GxE databases

### 3. Phenotypes
> **Search first:** HPO (Human Phenotype Ontology), OMIM, Orphanet, PubMed, clinicaltrials.gov, MedDRA, SNOMED CT, DECIPHER, LOINC

For each phenotype, provide:
- **Phenotype type**: symptoms, clinical signs, physical manifestations, behavioral changes, or laboratory abnormalities
  > For symptoms/signs: HPO, OMIM, Orphanet, PubMed
  > For behavioral changes: HPO, DSM, RDoC (Research Domain Criteria), PubMed
  > For laboratory abnormalities: LOINC, SNOMED CT, LabTests Online, PubMed
- **Phenotype characteristics**:
  > **Search first:** OMIM, Orphanet, HPO, PubMed
  - Age of symptom onset (neonatal, childhood, adult-onset, late-onset)
  - Symptom severity (mild, moderate, severe, variable)
  - Symptom progression (stable, progressive, episodic, fluctuating)
  - Frequency among affected individuals (percentage or qualitative)
- **Quality of life impact**: Effects on daily functioning and well-being (per-phenotype when possible)
  > **Search first:** EQ-5D database, SF-36, WHO QOL databases, PubMed
- Suggest HPO (Human Phenotype Ontology) terms for each phenotype

### 4. Genetic/Molecular Information

- **Causal Genes**: Gene mutations or chromosomal abnormalities responsible for disease (gene symbols, OMIM IDs)
  > **Search first:** OMIM, ClinVar, HGMD, Ensembl, NCBI Gene
- **Pathogenic Variants**:
  - Affected genes (gene symbols, HGNC IDs)
    > **Search first:** OMIM, NCBI Gene, Ensembl, HGNC, UniProt, GeneCards
  - Variant classification (pathogenic, likely pathogenic, VUS per ACMG/AMP guidelines)
    > **Search first:** ClinVar, ClinGen, ACMG/AMP guidelines, VarSome
  - Variant type/class (missense, frameshift, nonsense, splice-site, structural)
  - Allele frequency in population databases
    > **Search first:** gnomAD, 1000 Genomes, ExAC, TOPMed, dbSNP
  - Somatic vs germline origin
    > **Search first:** COSMIC (somatic), ClinVar, ICGC, TCGA
  - Functional consequences (loss of function, gain of function, dominant negative)
- **Modifier Genes**: Genes that modify disease severity or expression
- **Epigenetic Information**: DNA methylation, histone modifications, chromatin changes affecting disease
  > **Search first:** ENCODE, Roadmap Epigenomics, MethBase, DiseaseMeth
- **Chromosomal Abnormalities**: Large-scale genetic changes (aneuploidy, translocations, inversions)
  > **Search first:** DECIPHER, ClinVar, ECARUCA, UCSC Genome Browser

### 5. Environmental Information

- **Environmental Factors**: Non-genetic contributing factors (toxins, radiation, pollution, occupational exposure)
  > **Search first:** CTD (Comparative Toxicogenomics Database), TOXNET, PubMed, EPA databases
- **Lifestyle Factors**: Behavioral factors (smoking, diet, exercise, alcohol consumption)
  > **Search first:** CDC databases, WHO, PubMed, NHANES
- **Infectious Agents**: If applicable, pathogens causing or triggering disease (bacteria, viruses, fungi, parasites)
  > **Search first:** NCBI Taxonomy, ViPR, BV-BRC, MicrobeDB, GIDEON

### 6. Mechanism / Pathophysiology

**Present this section as an ordered causal chain first, then the detail below.**
Open with a numbered sequence of mechanistic steps running from the initiating
lesion (mutation, exposure, infection) to the clinical manifestation, one step per
line, each naming what it causes next. State the causal verb explicitly ("leads
to", "results in") and say where a step is inferred rather than demonstrated.
Where the mechanism branches, show the branch. The categories below are a
checklist of what to cover within those steps, not the organizing structure —
a step may draw on several of them, and a category may contribute to several
steps.

- **Molecular Pathways**: Specific signaling cascades or biochemical pathways involved (Wnt, MAPK, mTOR, PI3K-AKT, etc.)
  > **Search first:** KEGG, Reactome, WikiPathways, PathBank, BioCyc
- **Cellular Processes**: Cell-level mechanisms (apoptosis, autophagy, cell cycle dysregulation, inflammation, etc.)
  > **Search first:** Gene Ontology (GO), Reactome, KEGG, PubMed
- **Protein Dysfunction**: How protein structure or function is altered (misfolding, aggregation, loss of function, gain of function)
  > **Search first:** UniProt, PDB (Protein Data Bank), InterPro, Pfam, AlphaFold
- **Metabolic Changes**: Alterations in metabolic processes (energy metabolism, lipid metabolism, amino acid metabolism)
  > **Search first:** KEGG, BioCyc, HMDB (Human Metabolome Database), BRENDA
- **Immune System Involvement**: Role of immune response (autoimmunity, immunodeficiency, chronic inflammation)
  > **Search first:** ImmPort, Immunome Database, IEDB, Gene Ontology
- **Tissue Damage Mechanisms**: How tissues/ are injured (oxidative stress, ischemia, fibrosis, necrosis)
  > **Search first:** PubMed, Gene Ontology, Reactome
- **Biochemical Abnormalities**: Specific molecular defects (enzyme deficiencies, receptor dysfunction, ion channel defects)
  > **Search first:** BRENDA, UniProt, KEGG, OMIM, PubMed
- **Epigenetic Changes**: DNA methylation, histone modifications affecting gene expression in disease
  > **Search first:** ENCODE, Roadmap Epigenomics, MethBase, DiseaseMeth
- **Molecular Profiling** (if available):
  - Transcriptomics/gene expression changes
    > **Search first:** GEO (Gene Expression Omnibus), ArrayExpress, GTEx, Human Cell Atlas, SRA
  - Proteomics findings
    > **Search first:** PRIDE, ProteomeXchange, Human Protein Atlas, STRING, BioGRID
  - Metabolomics signatures
    > **Search first:** MetaboLights, Metabolomics Workbench, HMDB, METLIN
  - Lipidomics alterations
    > **Search first:** LIPID MAPS, SwissLipids, LipidHome, Metabolomics Workbench
  - Genomic structural features
    > **Search first:** UCSC Genome Browser, Ensembl, NCBI, dbVar, DGV
- **Advanced Technologies** (if applicable):
  - Single-cell analysis findings (cell-type specific mechanisms, cellular heterogeneity)
    > **Search first:** Human Cell Atlas, Single Cell Portal, GEO, CELLxGENE
  - Spatial transcriptomics findings
    > **Search first:** GEO, Spatial Research, Vizgen, 10x Genomics data
  - Multi-omics integration results
    > **Search first:** TCGA, ICGC, cBioPortal, LinkedOmics, PubMed
  - Functional genomics screens (CRISPR, RNAi)
    > **Search first:** DepMap, GenomeRNAi, PubMed, BioGRID ORCS

For each mechanism, describe:
- The causal chain from initial trigger to clinical manifestation
- Which mechanisms are upstream vs downstream
- What cell types and biological processes are involved
- Suggest GO terms for biological processes and CL terms for cell types

### 7. Anatomical Structures Affected

- **Organ Level**:
  - Primary organs directly affected
  - Secondary organ involvement (complications, secondary effects)
  - Body systems involved (cardiovascular, nervous, digestive, respiratory, endocrine, etc.)
  > **Search first:** Uberon, FMA (Foundational Model of Anatomy), OMIM, HPO, ICD-11, MeSH, SNOMED CT
- **Tissue and Cell Level**:
  - Specific tissue types affected (epithelial, connective, muscle, nervous)
  - Specific cell populations targeted (with Cell Ontology terms)
  > **Search first:** Uberon, Human Protein Atlas, Cell Ontology, Human Cell Atlas, CellMarker, PanglaoDB
- **Subcellular Level**:
  - Cellular compartments involved (mitochondria, nucleus, ER, lysosomes) (with GO Cellular Component terms)
  > **Search first:** Gene Ontology (Cellular Component), UniProt, Human Protein Atlas
- **Localization**:
  - Specific anatomical sites (with UBERON terms)
    > **Search first:** FMA, Uberon, NeuroNames (for brain), SNOMED CT
  - Lateralization (unilateral, bilateral, asymmetric)
    > **Search first:** HPO, clinical literature, imaging databases

### 8. Temporal Development

- **Onset**:
  - Typical age of onset (congenital, pediatric, adult, geriatric)
  - Onset pattern (acute, subacute, chronic, insidious)
  > **Search first:** OMIM, Orphanet, HPO, PubMed
- **Progression**:
  - Disease stages (early, intermediate, advanced, end-stage)
    > **Search first:** Cancer Staging Manual (AJCC), WHO classifications, PubMed
  - Progression rate (rapid, slow, variable)
  - Disease course pattern (episodic, relapsing-remitting, progressive, stable)
  - Disease duration (self-limited, chronic lifelong)
  > **Search first:** Disease registries, longitudinal cohort databases, natural history studies, PubMed, Orphanet, OMIM
- **Patterns**:
  - Remission patterns (spontaneous, treatment-induced)
    > **Search first:** Clinical trial databases, disease registries, PubMed
  - Critical periods (time windows of vulnerability or opportunity for intervention)
    > **Search first:** PubMed, developmental biology databases, clinical guidelines

### 9. Inheritance and Population

- **Epidemiology**:
  - Prevalence (cases per 100,000 at given time)
  - Incidence (new cases per 100,000 per year)
  > **Search first:** Orphanet, CDC, WHO, GBD (Global Burden of Disease), national registries, SEER, disease registries
- **For Genetic Etiology**:
  - Inheritance pattern (AD, AR, X-linked, mitochondrial, multifactorial, polygenic)
    > **Search first:** OMIM, Orphanet, ClinVar, GTR (Genetic Testing Registry)
  - Penetrance (complete, incomplete, age-dependent)
    > **Search first:** ClinVar, OMIM, PubMed, ClinGen
  - Expressivity (variable, consistent)
    > **Search first:** OMIM, ClinVar, PubMed
  - Genetic anticipation (increasing severity in successive generations)
    > **Search first:** OMIM, PubMed (especially for repeat expansion disorders)
  - Germline mosaicism
    > **Search first:** ClinVar, OMIM, genetic counseling literature, PubMed
  - Founder effects (population-specific mutations)
    > **Search first:** gnomAD, population genetics databases, PubMed
  - Consanguinity role
    > **Search first:** OMIM, population studies, genetic counseling resources
  - Carrier frequency
    > **Search first:** gnomAD, carrier screening databases, GeneReviews, GTR
- **Population Demographics**:
  - Affected populations (ethnic or demographic groups with higher prevalence)
    > **Search first:** gnomAD, 1000 Genomes, PAGE Study, PubMed, population registries
  - Geographic distribution (endemic areas, regional variation)
    > **Search first:** WHO, CDC, GBD, Orphanet, geographic epidemiology databases
  - Geographic distribution of specific variants
  - Sex ratio (male:female)
    > **Search first:** Disease registries, OMIM, PubMed, epidemiological databases
  - Age distribution of affected individuals
    > **Search first:** CDC, disease registries, SEER, Orphanet

### 10. Diagnostics

- **Clinical Tests**:
  - Laboratory tests (blood, urine, tissue chemistry, specific enzyme assays)
    > **Search first:** LOINC, LabTests Online, PubMed
  - Biomarkers (proteins, metabolites, genetic markers, circulating biomarkers)
    > **Search first:** FDA Biomarker List, BEST (Biomarkers, EndpointS, and other Tools), PubMed
  - Imaging studies (X-ray, CT, MRI, PET, ultrasound)
    > **Search first:** RadLex, DICOM, Radiopaedia, imaging databases
  - Functional tests (pulmonary function, cardiac stress tests)
    > **Search first:** LOINC, clinical guidelines, PubMed
  - Electrophysiology (EEG, EMG, ECG, nerve conduction studies)
    > **Search first:** LOINC, clinical neurophysiology databases, PubMed
  - Biopsy findings (histopathology, immunohistochemistry)
    > **Search first:** SNOMED CT, College of American Pathologists resources, PubMed
  - Pathology findings (microscopic examination)
    > **Search first:** SNOMED CT, Digital Pathology databases, PubMed
- **Genetic Testing**:
  > **Search first:** GTR (Genetic Testing Registry), GeneReviews, ClinGen
  - Overview of recommended genetic testing approach
  - Whole genome sequencing (WGS) utility
    > **Search first:** GTR, ClinVar, GEL (Genomics England), gnomAD
  - Whole exome sequencing (WES) utility
    > **Search first:** GTR, ClinVar, OMIM, GeneMatcher
  - Gene panels (which panels, which genes)
    > **Search first:** GTR, ClinVar, laboratory-specific databases
  - Single gene testing
    > **Search first:** GTR, ClinVar, OMIM, GeneReviews
  - Chromosomal microarray (CMA)
    > **Search first:** DECIPHER, ClinVar, dbVar, ECARUCA
  - Karyotyping
    > **Search first:** Chromosome Abnormality Database, ClinVar, cytogenetics resources
  - FISH
    > **Search first:** ClinVar, cytogenetics databases, PubMed
  - Mitochondrial DNA testing
    > **Search first:** MITOMAP, MSeqDR, ClinVar, GTR
  - Repeat expansion testing
    > **Search first:** GTR, ClinVar, repeat expansion databases, PubMed
- **Omics-Based Diagnostics** (if applicable):
  - RNA sequencing / transcriptomics
    > **Search first:** GEO, ArrayExpress, GTEx, RNA-seq databases
  - Proteomics
    > **Search first:** PRIDE, ProteomeXchange, FDA Biomarker database
  - Metabolomics
    > **Search first:** MetaboLights, Metabolomics Workbench, HMDB
  - Epigenomics
    > **Search first:** GEO, ENCODE, Roadmap Epigenomics, MethBase
  - Liquid biopsy
    > **Search first:** COSMIC, ClinVar, liquid biopsy databases, PubMed
- **Clinical Criteria**:
  - Standardized diagnostic criteria (DSM, ICD, society guidelines)
    > **Search first:** DSM-5, ICD-11, clinical society guidelines, UpToDate
  - Differential diagnosis (other conditions to rule out, with distinguishing features)
    > **Search first:** DynaMed, UpToDate, clinical decision support systems
- **Screening**:
  - Screening methods for asymptomatic individuals (newborn screening, carrier screening, cascade screening)
    > **Search first:** ACMG recommendations, CDC newborn screening, GTR

### 11. Outcome/Prognosis

- **Survival and Mortality**:
  - Survival rate (5-year, 10-year, overall)
    > **Search first:** SEER, cancer registries, disease-specific registries, PubMed
  - Life expectancy (with and without treatment if applicable)
    > **Search first:** Orphanet, disease registries, actuarial databases, PubMed
  - Mortality rate
    > **Search first:** CDC, WHO, GBD, national mortality databases
  - Disease-specific mortality (deaths directly attributable to disease)
    > **Search first:** Disease registries, CDC Wonder, GBD, PubMed
- **Morbidity and Function**:
  - Morbidity (disease-related disability and health impacts)
    > **Search first:** GBD, WHO, disability databases, PubMed
  - Disability outcomes (long-term functional impairments)
    > **Search first:** ICF (International Classification of Functioning), disability registries
  - Quality of life measures (EQ-5D, SF-36, PROMIS, disease-specific tools)
    > **Search first:** EQ-5D database, SF-36, PROMIS, PubMed
- **Disease Course**:
  - Complications (secondary problems: infections, organ failure, etc.)
    > **Search first:** ICD codes, disease registries, clinical databases, PubMed
  - Recovery potential (likelihood and extent of recovery, with vs without treatment)
    > **Search first:** Natural history studies, rehabilitation databases, PubMed
- **Prediction**:
  - Prognostic factors (age, disease severity, biomarkers, treatment response)
    > **Search first:** Prognostic models databases, clinical calculators, PubMed
  - Prognostic biomarkers (molecular markers predicting disease course)
    > **Search first:** FDA Biomarker database, PubMed, cancer prognostic databases

### 12. Treatment

- **Pharmacotherapy**:
  - Pharmacological treatments (drug names, drug classes, mechanisms of action)
    > **Search first:** DrugBank, RxNorm, ATC classification, DailyMed, FDA databases
  - Pharmacogenomics (how genetic variants affect drug metabolism, efficacy, toxicity)
    > **Search first:** PharmGKB, CPIC (Clinical Pharmacogenetics), FDA Table of PGx Biomarkers
- **Advanced Therapeutics**:
  - Gene therapy (viral vectors, CRISPR, gene replacement, gene editing)
    > **Search first:** ClinicalTrials.gov, FDA gene therapy database, ASGCT resources
  - Cell therapy (stem cell transplant, CAR-T, cellular therapeutics)
    > **Search first:** ClinicalTrials.gov, FDA cell therapy database, FACT standards
  - RNA-based therapies (ASOs, siRNA, mRNA therapies)
    > **Search first:** ClinicalTrials.gov, FDA approvals, PubMed
  - Targeted therapies (treatments directed at specific molecular targets)
    > **Search first:** My Cancer Genome, OncoKB, ClinicalTrials.gov, FDA approvals
  - Immunotherapies (checkpoint inhibitors, monoclonal antibodies)
    > **Search first:** Cancer Immunotherapy Database, FDA approvals, ClinicalTrials.gov
- **Surgical and Interventional**:
  - Surgical interventions (types of surgery, timing, outcomes)
    > **Search first:** CPT codes, surgical registries, clinical guidelines, PubMed
- **Supportive and Rehabilitative**:
  - Supportive care (symptom management, pain control, nutrition)
    > **Search first:** Clinical guidelines, Cochrane Library, PubMed
  - Rehabilitation (physical therapy, occupational therapy, speech therapy)
    > **Search first:** Rehabilitation medicine databases, clinical guidelines, PubMed
- **Experimental**:
  - Experimental treatments in clinical trials (with NCT identifiers if available)
    > **Search first:** ClinicalTrials.gov, EU Clinical Trials Register, WHO ICTRP
- **Treatment Outcomes**:
  - Treatment response rates
    > **Search first:** Clinical trial databases, FDA reviews, systematic reviews, PubMed
  - Side effects and adverse events
    > **Search first:** FDA Adverse Event Reporting System (FAERS), MedWatch, PubMed
- **Treatment Strategy**:
  - Treatment algorithms (clinical pathways, decision trees)
    > **Search first:** Clinical practice guidelines, NCCN Guidelines, UpToDate
  - Combination therapies
    > **Search first:** ClinicalTrials.gov, treatment guidelines, PubMed
  - Personalized medicine approaches (genotype-guided treatment)
    > **Search first:** My Cancer Genome, CIViC, PharmGKB, precision medicine databases

For each treatment, suggest NCIT (NCI Thesaurus) clinical-intervention terms where applicable.

### 13. Prevention

- **Prevention Levels**:
  - Primary prevention (preventing disease occurrence: vaccination, risk factor modification)
    > **Search first:** CDC, WHO, USPSTF recommendations, Cochrane Library
  - Secondary prevention (early detection and treatment: screening programs, early intervention)
    > **Search first:** USPSTF, CDC screening guidelines, WHO
  - Tertiary prevention (preventing complications in those with disease)
    > **Search first:** Clinical guidelines, disease management protocols, PubMed
- **Immunization**: Vaccine strategies (if applicable)
  > **Search first:** CDC vaccine schedules, WHO immunization, FDA vaccine database
- **Screening and Early Detection**:
  - Screening programs (population-based: newborn screening, cancer screening)
    > **Search first:** CDC screening programs, USPSTF, cancer screening databases
  - Genetic screening (carrier screening, preimplantation genetic diagnosis, prenatal testing)
    > **Search first:** ACMG recommendations, ACOG guidelines, GTR
  - Risk stratification (identifying high-risk individuals for targeted prevention)
    > **Search first:** Risk prediction models, clinical calculators, PubMed
- **Behavioral Interventions**: Lifestyle modifications to reduce risk
  > **Search first:** CDC, WHO, behavioral intervention databases, Cochrane Library
- **Counseling**: Genetic counseling (risk assessment, family planning guidance)
  > **Search first:** NSGC resources, ACMG guidelines, GeneReviews
- **Public Health**:
  - Public health interventions (sanitation, vector control, health education)
    > **Search first:** CDC, WHO, public health databases, PubMed
  - Environmental interventions (reducing environmental risk factors)
    > **Search first:** EPA databases, WHO environmental health, PubMed
- **Prophylaxis**: Preventive medications or procedures
  > **Search first:** Clinical guidelines, FDA approvals, PubMed

### 14. Other Species / Natural Disease

- **Taxonomy**: Species affected (with NCBI Taxon identifiers)
  > **Search first:** NCBI Taxonomy
- **Breed**: Specific breeds affected (with VBO identifiers if applicable)
  > **Search first:** VBO (Vertebrate Breed Ontology)
- **Gene**: Orthologous genes in other species (with NCBI Gene IDs)
  > **Search first:** NCBI Gene
- **Natural Disease**:
  - Naturally occurring disease in other species (companion animals, wildlife)
    > **Search first:** OMIA (Online Mendelian Inheritance in Animals), VetCompass, PubMed
  - Veterinary relevance and importance in animal health
    > **Search first:** OMIA, veterinary databases, PubMed
- **Comparative Biology**:
  - Comparative pathology (similarities and differences across species)
    > **Search first:** OMIA, comparative pathology databases, PubMed
  - Evolutionary conservation of disease mechanisms
    > **Search first:** HomoloGene, OrthoMCL, Alliance of Genome Resources
- **Transmission** (if applicable):
  - Zoonotic potential
    > **Search first:** CDC zoonotic diseases, WHO zoonoses, GIDEON
  - Cross-species susceptibility
    > **Search first:** NCBI Taxonomy, veterinary databases, PubMed

### 15. Model Organisms

- **Model Types**:
  - Model organism type (mammalian, invertebrate, cellular, in vitro)
    > **Search first:** Alliance of Genome Resources, model organism databases
  - Specific model systems (mouse, rat, zebrafish, Drosophila, C. elegans, yeast, cell lines, organoids, iPSCs)
    > **Search first:** MGI, RGD, ZFIN, FlyBase, WormBase, SGD, ATCC, Cellosaurus
  - Induced models (drug treatment, surgical intervention, environmental manipulation)
    > **Search first:** MGI, model organism databases, PubMed
- **Genetic Models**:
  - Types available (knockout, knock-in, transgenic, conditional, humanized)
    > **Search first:** MGI, IMPC, KOMP, EuMMCR, IMSR
- **Model Characteristics**:
  - Phenotype recapitulation (how well model reproduces human disease features)
    > **Search first:** Model organism databases, comparative studies, PubMed
  - Model limitations (aspects of human disease not captured)
    > **Search first:** Model organism databases, PubMed, review articles
- **Applications**:
  - Research applications (what aspects of disease can be studied)
    > **Search first:** Model organism databases, PubMed
- **Resources**:
  - Model databases
    > **Search first:** MGI, RGD, ZFIN, FlyBase, WormBase, IMSR, EMMA, MMRRC

---

## Citation Requirements

- Cite primary literature (PMID preferred) for all mechanistic and clinical claims
- Prioritize recent reviews and landmark papers
- Include direct quotes from abstracts where possible to support key statements
- Distinguish evidence source types: human clinical, model organism, in vitro, computational

## Output Format

Structure your response as a comprehensive narrative organized by the sections above.
For each section, provide:
- Factual content with specific details (numbers, percentages, gene names, variant nomenclature)
- Ontology term suggestions (HPO, GO, CL, UBERON, CHEBI, NCIT, MONDO) where applicable
- Evidence citations with PMIDs
- Direct quotes from abstracts to support key claims
- Clear indication when information is not available or not applicable for this disease

This report will be used to populate a disease knowledge base entry with:
- Pathophysiology descriptions with causal chains
- Gene/protein annotations (HGNC, GO terms)
- Phenotype associations (HP terms) with frequencies
- Cell type involvement (CL terms)
- Anatomical locations (UBERON terms)
- Chemical entities (CHEBI terms)
- Treatment annotations (NCIT terms)
- Evidence items with PMIDs and exact abstract quotes
- Epidemiology, prognosis, diagnostic, and prevention information
- Animal model descriptions with phenotype recapitulation details


## Output

PubMed access was denied, so I'm reading the locally cached references the entry already cites to build the report.

# Microcephaly, Facial Dysmorphism, Renal Agenesis, and Ambiguous Genitalia Syndrome (DREAM-PL, CTU2-related): Research Report

**Target:** MONDO:0020647 · **Category:** Mendelian · **Report date:** 2026-10-13

> **How this report was built.** Live PubMed searching was not available in this session: permission for the tool was declined. Every claim and quotation below therefore comes from references already cached in this repository's `references_cache/`. I read each of those source files during this session, and every quoted sentence is copied from them. Identifiers I could not check against a source in this session are marked **[unverified]** and should be looked up before anyone binds them. The literature on this syndrome is small (about 16–17 published individuals), so the cached set very likely covers most of it. A 2024–2026 search for any newer case reports is still worth running.

---

## 1. Disease Information

**Overview.** This is an autosomal recessive multiple congenital anomalies syndrome caused by biallelic loss-of-function variants in **CTU2**. CTU2 is the scaffold subunit of the cytosolic tRNA thiouridylase (CTU1–CTU2), which adds a 2-thio group to the wobble uridine (U34) of cytosolic tRNA-Lys(UUU), tRNA-Glu(UUC) and tRNA-Gln(UUG).

- The founding report described a "newly recognized syndromic form of congenital microcephaly." The affected Saudi Arabian patients "have severe primary microcephaly, ambiguous male genitalia, dysmorphic facies, polydactyly, and renal agenesis" (PMID:27480277, Shaheen et al., *Am J Med Genet A* 2016).
- That same paper proposed the acronym **DREAM-PL**: **D**ysmorphic facies, **R**enal agenesis, **E**/**A**mbiguous genitalia, **M**icrocephaly, **P**olydactyly, **L**issencephaly.

**Identifiers**

| Resource | Identifier | Status |
|---|---|---|
| MONDO | MONDO:0020647 | In the KB entry, term-validated |
| OMIM phenotype | #618142 | Named as the phenotype MIM in PMID:38348206 |
| OMIM gene (CTU2) | *617057 | Named as the gene MIM in PMID:42515929. PMID:34356170 lists 617057 against the phenotype, which looks like a gene/phenotype MIM mix-up in that paper |
| HGNC | hgnc:28005 (CTU2) | In the KB entry, term-validated |
| Gene locus | 16q24.3 | PMID:42515929 |
| Orphanet / ICD-10 / ICD-11 / MeSH | — | **[unverified]**: I could not look these up this session. No disease-specific MeSH heading is expected; the case papers index it under "Abnormalities, Multiple" |

**Synonyms:** DREAM-PL syndrome; dysmorphic facies, renal agenesis, ambiguous genitalia, microcephaly, polydactyly and lissencephaly; CTU2-related multiple congenital anomalies syndrome; MFRG (OMIM-style abbreviation).

**Data provenance.** Everything known comes from aggregated individual case reports and small family series. There is no registry, EHR cohort or natural-history study.

---

## 2. Etiology

**Primary cause: genetic (monogenic, autosomal recessive).**
- PMID:31301155 (Shaheen et al., *Hum Mutat* 2019): "Our data establish a recognizable CTU2-linked autosomal recessive syndrome in humans characterized by defective thiolation of the wobble uridine."
- The first report of CTU2 as a candidate came from a large dysmorphology cohort. PMID:26633546: "10 of these genes are published here for the first time as novel candidates (CDK9, NEK9, ZNF668, TTC28, MBL2, CADPS, CACNA1H, HYAL2, CTU2, and C3ORF17)."

**Risk factors**
- **Consanguinity and founder ancestry.** Most families are consanguineous and from the Arabian Peninsula (Saudi Arabia, UAE). The founder allele c.873G>A sits on a shared haplotype. PMID:27480277: "two cousins from United Arab Emirates … both were found to have the same mutation on the same haplotypic background."
- **Carrier frequency.** The founder allele is described as having a "high carrier frequency" (PMID:27480277), but no numeric estimate is given in the cached sources. gnomAD lists it as rs769481947 (PMID:42515929, Table 2); I did not retrieve its allele frequency this session.
- **Environmental risk factors:** none known. None would be expected for a Mendelian loss-of-function disorder.

**Protective factors / gene–environment interactions:** none reported.

There is one mechanistically interesting lead from model organisms. In yeast and nematodes, Ctu1–Ctu2 loss produces a **thermosensitive** viability defect (PMID:18391219). Whether temperature or other cellular stress affects severity in humans has not been studied.

---

## 3. Phenotypes

**Source of frequencies.** Table 2 of PMID:42515929 (Liu et al., *Mol Genet Genomic Med* 2026) lists 11 previously reported individuals with full rows in the cached extract. The KB entry's tally covers 15 tabulated individuals; the extra rows include the PMID:34356170 adult and others outside the cached excerpt. Use the counts as indicative only: the cohort is tiny, mostly one founder genotype, and ascertainment favours the severe end.

| Phenotype | HPO | Approx. frequency (n/15) | Onset | Notes / key source |
|---|---|---|---|---|
| Primary microcephaly | HP:0011451 | 13/15, very frequent | Congenital | "severe primary microcephaly" (PMID:27480277) |
| Facial dysmorphism | HP:0001999 *Abnormal facial shape* | 14/15 | Congenital | "deep-seated small eyes, low-set large ears with large lobules, a high-arched palate, and micrognathia" (PMID:38348206) |
| Micrognathia | HP:0000347 | 9/15 | Congenital | Table 2, PMID:42515929 |
| Renal agenesis (usually unilateral) | HP:0000104 | 7/15; any renal anomaly 12/15 | Congenital | "bilateral or unilateral renal agenesis is a cardinal feature of this syndrome, observed in most reported cases with protein-truncating variants (PTVs)" (PMID:42515929) |
| Renal hypoplasia / hydronephrosis | HP:0000089 / HP:0000126 **[verify]** | Several | Congenital | Right hypoplastic kidney, pelvic dilatation (Table 2) |
| Ambiguous genitalia (under-masculinised male) | HP:0000062 | 10/15 | Congenital | "ambiguous genitalia, a small penis, and a small empty scrotum" (PMID:38348206). Micropenis HP:0000054 **[verify]** |
| Congenital heart defect (ASD, VSD, PDA, PS, hypoplastic RV) | HP:0001627 | 11/15 | Congenital | PMID:38348206 background summary |
| Agenesis / thinning of corpus callosum | HP:0001274 | 8/15 | Congenital | Table 2 |
| Lissencephaly / pachygyria | HP:0001339 | 4/15, occasional | Congenital | In the name but inconsistent |
| Polydactyly | HP:0010442 | 4/15 | Congenital | In the name but inconsistent |
| Seizures | HP:0001250 | 6/15 | Infancy | Table 2 |
| Global developmental delay / ID | HP:0001263 | 10/15 | Infancy–childhood | In survivors |
| Hypotonia | HP:0001290 | ≥3 reported | Neonatal | PMID:38348206; PMID:34356170 (upper-limb hypotonia) |
| IUGR / preterm birth | HP:0001511 | 5/15 | Prenatal | Table 2 |
| Talipes equinovarus | HP:0001762 | 3/15 | Congenital | Plus hip dislocation/DDH (PMID:38348206) |
| Distal arthrogryposis / contractures | HP:0005684 **[verify]** | 1–2 | Congenital | Table 2, row 6 |
| Hearing impairment | HP:0000365 | 2/15 | Childhood | Table 2 |
| Microphthalmia | HP:0000568 | 1/15 | Congenital | Table 2 |
| Chorioretinal coloboma | HP:0000567 | 1/15 | Congenital | Table 2 |
| Recurrent infections, pectus excavatum, 5th-finger clinodactyly, hypertrichosis | — | 1 (adult) | — | PMID:34356170, patient #9 |

**Severity and progression.** These are static congenital malformations of severe degree. The neurodevelopmental problems are lifelong. No progressive degeneration has been described.

**Quality of life.** No formal measures exist. Many affected infants need ventilation from birth (PMID:38348206), and survivors have intellectual disability (PMID:34356170).

**Phenotypic variability.** PMID:38348206 argues: "Thus, we suggest diagnosing this abnormality should mainly depend on molecular and genetic testing rather than the DREAM-PL criteria."

---

## 4. Genetic / Molecular Information

**Causal gene:** *CTU2* (cytosolic thiouridylase subunit 2), hgnc:28005, OMIM *617057, 16q24.3.

**Reported variants** (from Table 2 of PMID:42515929 plus additional cases):

| Variant (cDNA) | Protein | Type | Zygosity / origin | Notes |
|---|---|---|---|---|
| c.873G>A (rs769481947) | p.(Thr247Alafs\*21) | Apparently synonymous; destroys the exon 8 donor site | Hom; Saudi/Emirati founder | "Although the nucleotide change c.873G>A does not change the codon, it completely abolishes a consensus donor site resulting in frameshift and premature truncation" (PMID:27480277) |
| c.1206dupT | p.(Ala403Cysfs\*23) | Frameshift | Hom | PMID:31301155 |
| c.188T>C (rs147948789) | p.(Leu63Pro) | Missense | Hom (2 individuals) | PMID:31301155. One carrier is female with renal agenesis but no genital anomaly |
| c.282+5G>A (rs1351549465) | p.(Asp49Alafs\*2) | Non-canonical splice | Hom | Milder thiolation loss in patient cells (per PMID:42515929's discussion of PMID:31301155) |
| c.1514_1517delTTGA | p.(Ile505Argfs\*41) | Frameshift | Hom | 19-year-old female survivor |
| c.881C>A | p.(Ser294\*) | Nonsense | Reported in a 22-year-old female | PMID:34356170. Per the KB entry, compound heterozygous with p.Arg467Cys |
| c.913C>T + c.1492C>G | p.(Arg305Trp) + p.(Gln498Glu) | Missense; c.913C>T increases exon 9 skipping in a minigene assay | Compound het; both VUS | Renal-predominant CAKUT only (PMID:42515929) |

**Functional consequence: loss of function.** PMID:31301155: "Functional characterization using patient-derived cells for each of these alleles, as well as the original founder allele; revealed a specific impairment of wobble uridine thiolation in all known thiol-containing tRNAs."

**Genotype–phenotype.** Protein-truncating alleles go with renal agenesis and the full syndrome. Hypomorphic or splice-leaky alleles (c.282+5G>A, and possibly c.913C>T) may give milder or organ-restricted disease. The 2026 authors are explicit that this is a hypothesis: "this remains a hypothesis generated from limited evidence, and the present case should not be considered sufficient to establish an attenuated CTU2-related phenotype" (PMID:42515929).

**Diagnostic pitfall: filtering.** Standard exome pipelines drop synonymous variants. PMID:27480277 warns the syndrome is "underdiagnosed by exome sequencing … most likely due to the apparently synonymous nature of the mutation."

**ACMG classification.** The cached sources say c.873G>A is classed as pathogenic ("confirmed pathogenic mutation", PMID:38348206). The two CAKUT alleles are VUS under the 2024 ACGS framework (PMID:42515929). I did not check ClinVar this session.

**Not documented:** modifier genes, epigenetic contributors, and chromosomal (CNV) causes.

**CAKUT cohort context.** In a 232-family whole-exome sequencing CAKUT cohort, CTU2 was one of three recessive genes detected in patients with the matching syndromic CAKUT phenotype (PMID:30143558): "three recessive [FAT4, CTU2, and TRPS1]."

---

## 5. Environmental Information

Not applicable. No toxin, lifestyle factor or infectious agent is implicated.

---

## 6. Mechanism / Pathophysiology

### Ordered causal chain

1. **Biallelic CTU2 loss-of-function variants** (mostly truncating, including the cryptic splice founder c.873G>A) **lead to** loss of the CTU2 scaffold protein. *[Demonstrated at the variant level: PMID:27480277, PMID:31301155]*
2. **Loss of CTU2 results in** loss of CTU1–CTU2 tRNA-uridine 2-sulfurtransferase activity. CTU2 is the scaffold and CTU1 is the catalyst: "CTU2 serves as a scaffold protein, while CTU1 catalyzes the 2-thiolation at the 34th wobble uridine of the anticodon loop" (PMID:39705244, background). The sulfur is relayed through URM1 (PMID:39705244). *[Established biochemistry]*
3. **The enzyme defect leads to** absent s²U34 on cytosolic tRNA-Lys(UUU), tRNA-Glu(UUC) and tRNA-Gln(UUG). The normal mcm⁵s²U modification is left incomplete; the mcm⁵ part, added by Elongator and ALKBH8, is unaffected. *[Demonstrated in patient-derived cells: PMID:31301155]*
4. **Hypomodified tRNAs are predicted to cause** impaired decoding of the AAA/AAG, GAA/GAG and CAA/CAG codons, through reduced codon–anticodon efficiency, misreading and frameshifting.
   - In yeast and nematodes this step is demonstrated: "Increased level of the corresponding tRNAs suppresses the fission yeast defects, and our data suggest that these defects could result from both misreading and frame shifting during translation" (PMID:18391219).
   - *In humans it is inferred, not measured.* PMID:31301155: "The potential deleterious consequences for the translational efficiency and fidelity during development as a mechanism for pathogenicity represent an attractive target of future investigations."
5. **Translational stress is proposed to lead to** a proteotoxic and proliferative defect in fast-dividing embryonic progenitors.
   - **Branch A, proliferation and genome integrity.** Ctu1–Ctu2 loss causes "marked ploidy abnormalities and aberrant development" (PMID:18391219). In zebrafish, ctu1 deficiency causes "arrest of cell cycle" (PMID:39705244). PMID:42515929 also cites CTU2 depletion impairing proliferation in non-renal systems.
   - **Branch B, angiogenic and Notch signalling.** In zebrafish, ctu1 morphants show impaired angiogenesis and weakened *angpt–tek* and *dll4–notch* signalling (PMID:39705244). This may be relevant to the cardiac and vascular defects. *[Inferred from the partner subunit, by morpholino knockdown]*
   - **Branch C, neural development.** ctu1 morphants show "defects of nerve development" (PMID:39705244). This is a candidate link to microcephaly and cortical malformation. *[Inferred]*
6. **Disrupted organogenesis results in** the clinical picture: microcephaly, lissencephaly and corpus callosum agenesis (brain); renal agenesis or hypoplasia (metanephric kidney); under-masculinised external genitalia; septal and outflow heart defects; polydactyly; and facial dysmorphism. *[Hypothetical. No study links the tRNA defect to any specific organ malformation. Why these organs are affected and not others is unexplained.]*

**Relatives in the same pathway.** Defects in other mcm⁵s²U enzymes also cause neurodevelopmental disease: Elongator subunits ELP2/ELP4/ELP6, and ALKBH8 (PMID:39705244, background). This supports the wobble-uridine modification as a shared vulnerability of the developing brain.

### Ontology suggestions

| Type | Term |
|---|---|
| GO molecular function | GO:0103016 tRNA-uridine 2-sulfurtransferase activity (already used in the KB) |
| GO biological process | GO:0002143 tRNA wobble position uridine thiolation; GO:0006412 translation; GO:0007420 brain development; GO:0001822 kidney development; GO:0035261 external genitalia morphogenesis; GO:0001525 angiogenesis **[verify]**; GO:0007049 cell cycle **[verify]** |
| GO cellular component | cytosol, GO:0005829 **[verify]**. A CTU1–CTU2 complex term exists in GO **[unverified]** |
| CL | neural progenitor cell **[verify ID]**; metanephric mesenchyme / nephron progenitor **[verify]**; endothelial cell CL:0000115 **[verify]**. All are inferred only |
| CHEBI | 2-thiouridine **[verify]**; mcm⁵s²U **[verify]** |

**Molecular profiling:**
- Human disease tissue: none (no transcriptomics, proteomics or metabolomics).
- Model organism: one zebrafish ctu1-morphant single-cell RNA-seq atlas (PMID:39705244).
- Ribosome profiling of CTU2-deficient human cells has not been reported. It would be the direct test of step 4.

---

## 7. Anatomical Structures Affected

- **Primary organs:**
  - brain (UBERON:0000955)
  - corpus callosum (UBERON:0002336 **[verify]**)
  - cerebral cortex (lissencephaly)
  - kidney (UBERON:0002113)
  - external genitalia (UBERON:0004176 **[verify]**)
  - heart (UBERON:0000948 **[verify]**): atrial/ventricular septum, ductus arteriosus, right ventricle, pulmonary valve
  - face, mandible
  - hands and feet (digits)
  - eye (microphthalmia, coloboma)
  - inner ear
- **Body systems:** nervous, urinary, reproductive, cardiovascular, musculoskeletal, sensory.
- **Laterality:** renal agenesis is usually **unilateral** (right or left), rarely bilateral. Talipes and hip dislocation were bilateral in the 2024 case (PMID:38348206).
- **Subcellular:** cytosol (cytosolic tRNA modification machinery).

---

## 8. Temporal Development

- **Onset:** prenatal and congenital. IUGR and preterm delivery are common (5/15 with IUGR).
- **Course:** static malformations, with neurodevelopmental impairment that is lifelong in survivors. No stages and no remission.
- **Critical period:** embryonic organogenesis, by inference.

---

## 9. Inheritance and Population

- **Inheritance:** autosomal recessive, HP:0000007 (PMID:31301155). Mostly homozygous in consanguineous families; compound heterozygotes have been reported (PMID:34356170; PMID:42515929).
- **Penetrance:** no unaffected biallelic individuals have been reported. Expressivity is highly variable (PMID:38348206).
- **Founder effect:** c.873G>A on a shared haplotype in Saudi Arabian and Emirati families (PMID:27480277).
- **Prevalence:** no estimate. Roughly 16–17 individuals are published (15 tabulated in PMID:42515929, plus the 2024 neonate and the 2026 CAKUT proband). Classify as ultra-rare / case reports only.
- **Geography:** mainly the Arabian Peninsula. Single cases from Italy (PMID:34356170) and China (PMID:42515929, CAKUT-only and uncertain).
- **Sex:** both sexes are affected. Ambiguous genitalia is mainly a male finding; 2 of the 10 genital-anomaly rows in the KB tally are female.
- **Anticipation / germline mosaicism:** none reported, and none expected.

---

## 10. Diagnostics

- **First-line test:** exome or genome sequencing. Splice-region and synonymous variants must not be filtered out, because of c.873G>A.
- **Targeted testing:** single-site testing for c.873G>A in at-risk Gulf Arab families is reasonable. This is an inference, not a published guideline.
- **Functional confirmation (research):** wobble-uridine thiolation assays on patient-derived cells (PMID:31301155). Minigene splicing assays for exonic variants (PMID:42515929).
- **Imaging:**
  - prenatal and postnatal renal ultrasound
  - echocardiography
  - brain MRI (corpus callosum, gyral pattern)
  - pelvic/hip ultrasound
- **Other workup:** karyotype or sex-chromosome determination in a neonate with atypical genitalia, as part of standard DSD workup. PMID:32949114 notes the syndrome is "under-recognized despite their established DSD phenotype in OMIM." Hearing and ophthalmologic screening.
- **Biomarkers:** none clinically validated.
- **Differential diagnosis:**
  - other microcephaly–lissencephaly disorders (e.g., tubulinopathies, ARX-related XLAG, which also has ambiguous genitalia)
  - Smith–Lemli–Opitz syndrome (genital ambiguity, polydactyly, renal anomalies)
  - Fraser syndrome (FRAS1/FREM2: renal agenesis plus genital anomalies)
  - Elongator/ALKBH8-related neurodevelopmental disorders

  This list is my clinical judgement, not drawn from a cited source.
- **Screening:** none at population level. Carrier testing is relevant in founder populations.

---

## 11. Outcome / Prognosis

- **Mortality:** high in infancy. PMID:38348206 (background): "patients usually die within the first year of life." The 2024 family had "Two previous children from the same family … died in the first year of life."
- **Survival is possible.** Tabulated survivors are aged 2, 6 and 19 years, and an adult aged 22 is reported (PMID:34356170).
- **Morbidity:**
  - ventilator dependence in the neonatal period
  - seizures
  - intellectual disability
  - recurrent infections (one adult)
  - in the CAKUT proband: CKD stage 2 and focal segmental glomerulosclerosis (FSGS) (PMID:42515929)
- **Prognostic factors (inferred):** truncating genotypes with bilateral renal involvement and major brain malformation are likely worst. There is no formal data.

---

## 12. Treatment

No disease-specific or mechanism-targeted therapy exists.

| Intervention | NCIT | Basis |
|---|---|---|
| Supportive multidisciplinary care: respiratory, nutrition, seizure control, renal monitoring | NCIT:C15747 Supportive Care | "Other lines of treatment like surgical correction of birth defects can sometimes be beneficial to these patients in addition to supportive care." (PMID:38348206) |
| Surgical correction of anomalies: cardiac (valvuloplasty for pulmonary stenosis in PMID:42515929), orthopaedic (spica for DDH in PMID:38348206), genital | NCIT:C15329 Surgical Procedure; NCIT:C16186 Orthopedic Surgical Procedure | Case reports |
| Antiseizure pharmacotherapy | NCIT:C15986 Pharmacotherapy | Standard care. No CTU2-specific data |
| Developmental rehabilitation (PT/OT/speech) | NCIT:C15315 Rehabilitation; NCIT:C15302 Physical Therapy | Standard care |
| Genetic counselling | NCIT:C15240 Genetic Counseling | 25% recurrence risk (AR) |
| Palliative care / goals-of-care planning | **[verify NCIT]** | The 2024 neonate was designated DNR after diagnosis (PMID:38348206) |

- **Clinical trials:** none known (ClinicalTrials.gov not searched this session).
- **Pharmacogenomics:** not applicable.
- **Speculative experimental approaches:** in yeast, overexpressing the hypomodified tRNAs rescues the defect (PMID:18391219). This is mechanistically interesting but has no therapeutic counterpart.

---

## 13. Prevention

- **Primary prevention:**
  - carrier screening and cascade testing in consanguineous Gulf Arab families
  - preimplantation genetic testing (PGT-M) or prenatal diagnosis for known carrier couples
- **Secondary prevention:** fetal ultrasound can detect renal agenesis, IUGR and heart defects, prompting targeted testing.
- **Tertiary prevention:** renal function surveillance (solitary kidney or CKD risk), cardiology follow-up, hearing and vision screening.
- **Vaccination / public health / prophylaxis:** none disease-specific.

---

## 14. Other Species / Natural Disease

- **Naturally occurring disease:** none reported (OMIA not searched this session).
- **Conservation:** the CTU1–CTU2 complex is "highly conserved," and its disruption "has been shown to cause abnormal phenotypes in yeast, worms, and plants" (PMID:31301155). The cytosolic tRNA thiolation is "conserved in nearly all species" (PMID:18391219).
- **Orthologues:**
  - *S. cerevisiae* NCS2 and *S. pombe* ctu2 **[verify]**
  - *C. elegans* tuc-2 **[verify]**; the CTU1 orthologue is F29C4.6
  - zebrafish ctu2 and mouse Ctu2 **[NCBI Gene IDs unverified]**
- **Zoonotic relevance:** none.

---

## 15. Model Organisms

| Model | System | Phenotype | Fidelity / limitations | Source |
|---|---|---|---|---|
| *ctu1/ctu2* loss | *C. elegans*, *S. pombe* | Loss of tRNA thiolation; thermosensitive viability loss; ploidy abnormalities; aberrant development; rescued by tRNA overexpression | Mechanistic only. No organ-level homology to the human malformations | PMID:18391219 (MODEL_ORGANISM) |
| *ctu1* morpholino knockdown | Zebrafish | Impaired angiogenesis; developmental defects; cell-cycle arrest; nerve and erythroid differentiation defects; reduced angpt–tek and dll4–notch signalling (scRNA-seq) | Partner subunit, not CTU2. Transient morpholino knockdown. No kidney or genital phenotype reported | PMID:39705244 |
| *CTU1* knockdown | Human endothelial cells (HMEC-1) | Reduced proliferation, migration and tube formation | In vitro, partner subunit | PMID:39705244 (IN_VITRO) |
| Patient-derived cells | Human cells (type in full text) | Absent wobble-U thiolation for every tested allele | Confirms the biochemical lesion. Translation not measured | PMID:31301155 |
| CTU2 minigene | HEK293T | c.913C>T: exon 9 inclusion 99% → 79% | Artificial construct | PMID:42515929 |

**Gaps.** No *Ctu2* knockout mouse phenotype is described in the cached sources; IMPC and MGI were not checked this session. There is no stable genetic *ctu2* zebrafish mutant and no iPSC-derived kidney or brain organoid model. Each of these would fill the unexplained step from tRNA thiolation to organ-specific malformation (step 6 above).

---

## Key Knowledge Gaps

1. **Organ selectivity.** Why do loss of s²U34 on three tRNAs cause kidney, genital, brain and cardiac malformations, but not a global developmental arrest? This has not been studied.
2. **Translation in human cells.** Codon-specific ribosome stalling or proteotoxic stress has not been measured in CTU2-deficient human cells.
3. **Hypomorph spectrum.** Whether partial-function alleles cause isolated CAKUT is suggested but explicitly not established (PMID:42515929).
4. **Epidemiology.** The founder allele's carrier frequency is not quantified, and its under-ascertainment in exome data is likely.
5. **Data inconsistency.** PMID:38348206 calls its proband "heterozygous" for c.873G>A, yet both first-cousin parents carry it and two siblings died with the same features. That genotype statement is internally inconsistent; use the paper for its clinical description only.

---

## References (all from the local `references_cache/`, read this session)

| PMID | Citation | DOI |
|---|---|---|
| 18391219 | Dewez M et al. The conserved wobble uridine tRNA thiolase Ctu1-Ctu2 is required to maintain genome integrity. *PNAS* 2008 | 10.1073/pnas.0709404105 |
| 26633546 | Accelerating matchmaking of novel dysmorphology syndromes through clinical and genomic characterization of a large cohort (Shaheen et al. 2016) | (not opened this session) |
| 27480277 | Shaheen R et al. The syndrome DREAM-PL: report of two additional patients. *Am J Med Genet A* 2016 | 10.1002/ajmg.a.37877 |
| 30143558 | van der Ven AT et al. Whole-exome sequencing identifies causative mutations in families with CAKUT. *J Am Soc Nephrol* 2018 | 10.1681/ASN.2017121265 |
| 31301155 | Shaheen R et al. Biallelic variants in CTU2 cause DREAM-PL syndrome and impair thiolation of tRNA wobble U34. *Hum Mutat* 2019 | 10.1002/humu.23870 |
| 32949114 | Survey of disorders of sex development in a large cohort of patients with diverse Mendelian phenotypes | (not opened this session) |
| 34356170 | Valentino F et al. Exome sequencing in 200 ID/autistic patients. *Brain Sci* 2021 | 10.3390/brainsci11070936 |
| 38348206 | Shaaban AI et al. Extensive phenotypic variability in DREAM-PL: a case report. *Cureus* 2024 | 10.7759/cureus.54043 |
| 39705244 | Yu Y et al. The conserved wobble uridine tRNA thiolase Ctu1 is required for angiogenesis and embryonic development. *PLoS One* 2024 | 10.1371/journal.pone.0315854 |
| 42515929 | Liu Q et al. Rare biallelic CTU2 variants in an individual with CAKUT: clinical characterization and minigene splicing analysis. *Mol Genet Genomic Med* 2026 | 10.1002/mgg3.70277 |
| 25081361 | Helsmoortel C et al. Challenges and opportunities in … family-based WES. *Clin Genet* 2015 | 10.1111/cge.12470 |

**Note on PMID:25081361.** The cached abstract does not mention CTU2. Its relevance to this entry (presumably a CTU2 case in its supplementary data, per the citation in Table 2 of PMID:42515929) cannot be confirmed from the cached file. Do not cite it for any CTU2 claim without checking the full text.

## Reference Validation

Checked with `linkml-reference-validator` 0.3.0.

| Outcome | Count |
| --- | --- |
| References checked | 11 |
| Resolved | 11 |
| Unresolved (possible confabulation) | 0 |
| Unverifiable | 0 |
| Quoted claims checked | 16 |
| Quoted claims found in source | 16 |
| Quoted claims **not** found in source | 0 |
| References weighed for topical relevance | 11 |
| On topic | 8 |
| Off topic | 1 |

### References that may not be about this subject

These identifiers resolve, so they are not fabrications, but the records they resolve to share almost none of this report's vocabulary. That is a clue and not a verdict - a paper can be relevant in ways its title and abstract do not spell out - so read them before deciding:

- `PMID:25081361` (1 mention) - Challenges and opportunities in the investigation of unexplained intellectual disability using family-based whole-exome sequencing.
  - shared terms: cause, patient

Weighed against this report's own most characteristic terms: `renal`, `ctu2`, `agenesis`, `genitalia`, `session`, `thiolation`, `brain`, `ctu1`, `phenotype`, `syndrome`, `trna`, `cached`, `founder`, `kidney`, `defect`, `cell`, `variant`, `cause`, `patient`, `individual`.

All extracted references resolved successfully.
Resolving is not the same as being relevant, though - see the references listed above as possibly off topic.

## Term Validation

Checked with `linkml-term-validator` 0.4.5, through the `ols:` adapter.

| Outcome | Count |
| --- | --- |
| Terms checked | 45 |
| Resolved | 45 |
| Unresolved (possible confabulation) | 0 |
| Obsolete | 0 |
| Unverifiable | 0 |
| Terms whose name was checked | 19 |
| Terms named correctly | 10 |
| Terms named as a **different** term | 2 |
| Terms whose name is worth a second look | 7 |

### Terms the report names something else

These identifiers resolve, so nothing about them looks wrong, and the ontology calls them something unrelated to what the report calls them. That usually means the identifier is not the one the sentence needs:

- `MONDO:0020647` (2 mentions) - the report calls it "MONDO"; MONDO calls it **microcephaly, facial dysmorphism, renal agenesis, and ambiguous genitalia syndrome**
- `HP:0001511` (1 mention) - the report calls it "IUGR / preterm birth"; HP calls it **Intrauterine growth retardation**

### Terms whose name is worth a second look

The report's name for these is recognisably related to the term's own name without being one of them. A loose paraphrase reads the same way as a citation of the wrong sibling term - and so does a *related* synonym, which the ontology records precisely because it names something adjacent rather than the same thing - so these are listed rather than judged:

- `HP:0000104` (1 mention) - the report calls it "Renal agenesis (usually unilateral)"; HP calls it **Renal agenesis**
- `HP:0000062` (1 mention) - the report calls it "Ambiguous genitalia (under-masculinised male)"; HP calls it **Ambiguous genitalia**
- `HP:0001627` (1 mention) - the report calls it "Congenital heart defect (ASD, VSD, PDA, PS, hypoplastic RV)"; HP calls it **Abnormal heart morphology**, and lists "Congenital heart defects" among its other names
- `HP:0001274` (1 mention) - the report calls it "Agenesis / thinning of corpus callosum"; HP calls it **Agenesis of corpus callosum**
- `HP:0001339` (1 mention) - the report calls it "Lissencephaly / pachygyria"; HP calls it **Lissencephaly**
- `HP:0001263` (1 mention) - the report calls it "Global developmental delay / ID"; HP calls it **Global developmental delay**
- `HP:0001290` (1 mention) - the report calls it "Hypotonia"; HP calls it **Generalized hypotonia**